Want to see TSE:RVV full AI Analyst Report?
Revive Therapeutics (RVV) AI Stock Analysis
Revive Therapeutics
(CNQX:RVV)
Weak financial performance due to zero revenue and negative equity is the primary factor weighing on the score, followed by bearish technical indicators and unattractive valuation.
Revive Therapeutics (RVV) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 8.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 197.11K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- -1.35
- Revenue Growth
- ―
- EPS Growth
- 90.84%
- Country
- Canada
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Revive Therapeutics Business Overview & Revenue Model
Company Description
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory...
Revive Therapeutics Financial Statement Overview
Summary
Zero revenue, negative equity of $4 million, and ongoing cash burn highlight significant financial risks for this development-stage company, offset slightly by reduced losses.
Income Statement
18Very NegativeBalance Sheet
10Very NegativeCash Flow
27Negative| Breakdown | TTM | Jun 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -203 | -189 | -248 | -328 | -434 | -578 |
| EBITDA | -10.66M | -1.05M | -11.01M | -5.60M | -5.52M | -17.74M |
| Net Income | -10.62M | -1.02M | -11.01M | -5.62M | -6.32M | -17.83M |
Balance Sheet | ||||||
| Total Assets | 281.77K | 283.38K | 205.02K | 10.64M | 14.25M | 17.07M |
| Cash, Cash Equivalents and Short-Term Investments | 22.66K | 14.83K | 24.56K | 773.07K | 2.09M | 3.92M |
| Total Debt | 70.77K | 0 | 66.87K | 25.22K | 219.69K | 327.73K |
| Total Liabilities | 4.31M | 4.30M | 3.66M | 3.40M | 3.60M | 4.46M |
| Stockholders Equity | -4.02M | -4.02M | -3.46M | 7.23M | 10.65M | 12.60M |
Cash Flow | ||||||
| Free Cash Flow | -156.71K | -158.53K | -807.66K | -3.29M | -6.03M | -13.06M |
| Operating Cash Flow | -156.71K | -158.53K | -807.66K | -3.29M | -6.03M | -13.06M |
| Investing Cash Flow | 0 | 0 | -30.00K | 0 | 0 | 0 |
| Financing Cash Flow | 122.95K | 148.80K | 39.15K | 1.98M | 4.20M | 376.35K |
Revive Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 47.69 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVV.
Revive Therapeutics Peers Comparison
Overall Rating
TSE:RAMM41.7Neutral- TSE:RVV38Underperform
TSE:PCLO24Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:RAMM | 42Neutral | CAD 1.19M | -0.13 | -194.41% | ― | -66.40% | 31.38% |
| TSE:RVV | 38Underperform | CAD 8.37M | -0.83 | 288.66% | ― | ― | 90.84% |
| TSE:PCLO | 24Underperform | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:RVV | Revive Therapeutics | 0.02 | 0.01 | 100.00% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:RAMM | Ramm Pharma Corp | 0.01 | -0.01 | -50.00% |
Revive Therapeutics Corporate Events
Revive Therapeutics Moves to Build Global Bucillamine Franchise in Biodefence and Rare Diseases
PositiveRevive Therapeutics outlined a strategy to transform bucillamine into a globally protected therapeutic franchise spanning medical countermeasures, orphan diseases and government preparedness programs. The plan focuses on strengthening patent protecti...
Revive Therapeutics Moves to Settle Trade Debt Through Share Issuance
NeutralRevive Therapeutics has proposed a shares-for-debt settlement under which it plans to issue up to 1,221,516 common shares at a deemed price of $0.05 to extinguish $61,061 in outstanding trade payables owed to two arm’s length creditors. The tra...
Revive Therapeutics Sets Bucillamine-Led Strategy for Biodefence and Pandemic Countermeasures
PositiveRevive Therapeutics has outlined a strategy to build a focused portfolio of medical countermeasures for biodefence and pandemic preparedness, anchored by its drug candidate bucillamine. The plan aims to serve government and public-health buyers who r...
Revive Therapeutics Grants 15.5 Million Stock Options to Key Team Members
PositiveRevive Therapeutics has granted 15,500,000 incentive stock options to directors, officers and consultants, with an exercise price of $0.05 per share and a five-year term under its 10% rolling stock option plan. The move is positioned as a strategic t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 01, 2026